| 3.9908 -0.019 (-0.48%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.06 | 1-year : | 5.92 |
| Resists | First : | 4.34 | Second : | 5.06 |
| Pivot price | 3.92  |
|||
| Supports | First : | 3.38 | Second : | 2.79 |
| MAs | MA(5) : | 3.76  |
MA(20) : | 3.91 |
| MA(100) : | 3.94 |
MA(250) : | 3.89 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 32.6 |
D(3) : | 22.7 |
| RSI | RSI(14): 52.7 |
|||
| 52-week | High : | 5.96 | Low : | 2.77 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ XBIO ] has closed below upper band by 40.7%. Bollinger Bands are 11.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.14 - 4.15 | 4.15 - 4.17 |
| Low: | 3.88 - 3.89 | 3.89 - 3.91 |
| Close: | 3.96 - 3.99 | 3.99 - 4.02 |
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Fri, 13 Sep 2024
Xenetic Biosciences Inc (NASDAQ:XBIO) Sees Significant Decline in Short Interest - Defense World
Wed, 11 Sep 2024
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference - AccessWire
Wed, 14 Aug 2024
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update - AccessWire
Wed, 14 Aug 2024
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update - StockTitan
Tue, 13 Aug 2024
Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Fri, 10 May 2024
Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update - Kansas City Star
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 19 (%) |
| Held by Institutions | 0.9 (%) |
| Shares Short | 19 (K) |
| Shares Short P.Month | 1 (K) |
| EPS | -3.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.82 |
| Profit Margin | -186.4 % |
| Operating Margin | -184.2 % |
| Return on Assets (ttm) | -28.8 % |
| Return on Equity (ttm) | -48.7 % |
| Qtrly Rev. Growth | 11.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.63 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -1.31 |
| PEG Ratio | 0 |
| Price to Book value | 0.82 |
| Price to Sales | 2.43 |
| Price to Cash Flow | -1.8 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|